PURPOSE: To determine the safety, maximum tolerated dose,and biological effects of recombinant human IL-12 after autologous stem cell transplantation for cancer. EXPERIMENTAL DESIGN: Twelve patients with hematological malignancies (8 non-Hodgkin's lymphoma, 2 Hodgkin's disease, and 2 plasma cell myeloma) began interleukin (IL)-12 therapy at a median of 66 days after transplantation. Recombinant human IL-12 was given by bolus i.v. injection in doses of 30, 100, or 250 ng/kg once as an inpatient and then, after a 2-week hiatus, once daily for 5 consecutive days every 3 weeks on an outpatient basis. RESULTS: Common side effects included fever, chills, fatigue, nausea or vomiting, and asymptomatic elevation in serum liver function tests. Transient neutropenia and thrombocytopenia were also common, but no patient required platelet transfusion or had a neutropenic fever. Dose-limiting toxicities (diarrhea and elevated liver function tests) occurred in 2 of 3 patients treated in the 250 ng/kg cohort. Biological effects, including increases in serum IFN-gamma levels and transient lymphopenia involving CD4 T cells, CD8 T cells, B cells, and NK cells, were seen at all three dose levels. CONCLUSIONS: Biologically active doses of IL-12 can be given safely to patients after autologous stem cell transplantation for high-risk hematological malignancies. Further studies are indicated to assess the efficacy of IL-12 in this setting.
PURPOSE: To determine the safety, maximum tolerated dose,and biological effects of recombinant human IL-12 after autologous stem cell transplantation for cancer. EXPERIMENTAL DESIGN: Twelve patients with hematological malignancies (8 non-Hodgkin's lymphoma, 2 Hodgkin's disease, and 2 plasma cell myeloma) began interleukin (IL)-12 therapy at a median of 66 days after transplantation. Recombinant human IL-12 was given by bolus i.v. injection in doses of 30, 100, or 250 ng/kg once as an inpatient and then, after a 2-week hiatus, once daily for 5 consecutive days every 3 weeks on an outpatient basis. RESULTS: Common side effects included fever, chills, fatigue, nausea or vomiting, and asymptomatic elevation in serum liver function tests. Transient neutropenia and thrombocytopenia were also common, but no patient required platelet transfusion or had a neutropenic fever. Dose-limiting toxicities (diarrhea and elevated liver function tests) occurred in 2 of 3 patients treated in the 250 ng/kg cohort. Biological effects, including increases in serum IFN-gamma levels and transient lymphopenia involving CD4 T cells, CD8 T cells, B cells, and NK cells, were seen at all three dose levels. CONCLUSIONS: Biologically active doses of IL-12 can be given safely to patients after autologous stem cell transplantation for high-risk hematological malignancies. Further studies are indicated to assess the efficacy of IL-12 in this setting.
Authors: Ekambar R Kandimalla; Lakshmi Bhagat; Yukui Li; Dong Yu; Daqing Wang; Yan-Ping Cong; Sam S Song; Jimmy X Tang; Tim Sullivan; Sudhir Agrawal Journal: Proc Natl Acad Sci U S A Date: 2005-04-28 Impact factor: 11.205
Authors: Shivani Srivastava; David Pelloso; Hailin Feng; Larry Voiles; David Lewis; Zdenka Haskova; Margaret Whitacre; Stephen Trulli; Yi-Jiun Chen; John Toso; Zdenka L Jonak; Hua-Chen Chang; Michael J Robertson Journal: Cancer Immunol Immunother Date: 2013-04-19 Impact factor: 6.968
Authors: Michael J Robertson; Christopher W Stamatkin; David Pelloso; Jill Weisenbach; Nagendra K Prasad; Ahmad R Safa Journal: J Immunother Date: 2018-04 Impact factor: 4.456
Authors: Takuya Osada; Peter Berglund; Michael A Morse; Bolyn Hubby; Whitney Lewis; Donna Niedzwiecki; Xiao Yi Yang; Amy Hobeika; Bruce Burnett; Gayathri R Devi; Timothy M Clay; Jonathan Smith; H Kim Lyerly Journal: Cancer Immunol Immunother Date: 2012-04-10 Impact factor: 6.968
Authors: Ivan P Lupov; Larry Voiles; Ling Han; Allysia Schwartz; Manuel De La Rosa; Kinnari Oza; David Pelloso; Ravi P Sahu; Jeffrey B Travers; Michael J Robertson; Hua-Chen Chang Journal: Blood Date: 2011-10-13 Impact factor: 22.113
Authors: Hua-Chen Chang; Ling Han; Ritobrata Goswami; Evelyn T Nguyen; David Pelloso; Michael J Robertson; Mark H Kaplan Journal: Blood Date: 2009-04-09 Impact factor: 22.113
Authors: Maria Cecilia Rodriguez-Galan; Della Reynolds; Silvia G Correa; Pablo Iribarren; Morihiro Watanabe; Howard A Young Journal: J Immunol Date: 2009-06-17 Impact factor: 5.422